Skip to main content
Premium Trial:

Request an Annual Quote

QuantuMDx Gets $1.6M from UK Government for Drug-resistant TB Test

NEW YORK (GenomeWeb News) – QuantuMDx said today that it has received a £1 million ($1.6 million) grant from the UK government's Technology Strategy Board to fund a project to develop a rapid test for multi-drug resistant tuberculosis.

The Newcastle, UK-based molecular diagnostics company is involved in a three-year, £2 million effort to advance its Q-TB test, which will be used to analyze sputum samples for MDR-TB at the point-of-care within 15 minutes. Such a test would enable public health officials to identify areas where drug resistance is emerging and then treat those patients accordingly.

QuantuMDx said it plans to integrate its DNA analysis device and a TB biomarker panel developed by St. George's Hospital, University of London, and other partners into a test cartridge. This disposable cartridge will operate on the company's Q-POC handheld diagnostic device. It will use lab-on-chip technologies to extract, amplify, and detect the TB, and then to provide diagnostic and drug susceptibility results.

QuantuMDx Chief Scientific Officer and Co-founder Jonathan O'Halloran said that current methods for testing for MDR-TB are slow and expensive.

"The only way we can effectively treat and prevent the spread of MDR-TB is to perform rapid testing at the patients' side, enabling the immediate prescription of targeted drug treatments," he said.

He also said the device is "ideal" for use in the field, and may be used with hundreds or thousands of new disease markers as they are discovered.

The company has developed three other tests for use on its Q-POC platform, including a malaria speciation and drug resistance assay, a warfarin dosing companion diagnostic, and a tumor profiling test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.